=== PAGE 6 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Colin Vechery, PharmD
Novartis Pharmaceuticals Corporation
NDA 209092/MA 1344

Page 6

encouraged, but not required, to submit your response in eCTD format. All correspondence
submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.
Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 6861 under NDA 209092. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Koung Lee, RPh, MSHS
Regulatory Review Officer
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

{See appended electronic signature page}

Rachael Conklin, MS, RN, RAC
Team Leader
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

Reference ID: 5312143
